Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Benzinga · 5d ago
Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $11 price target.